The DRG1 Knockout HEK293T Polyclonal Cells provide a CRISPR/Cas9-mediated gene disruption of the developmentally regulated GTP-binding protein 1 (DRG1) in a human HEK293T background. This product is supplied as a polyclonal cell pool, wherein heterogeneous gene editing yields a diverse population of knockout cells, ideal for bulk functional studies. This format circumvents the need for single-cell cloning while enabling robust assessment of DRG1-dependent cellular processes.
HEK293T cells are a human embryonic kidney epithelial line stably expressing the SV40 large T antigen, conferring high transfection efficiency and episomal plasmid replication. Their rapid growth and proficient translational machinery make them a standard model for studying ribosome biogenesis, mTOR signaling, and stress granule dynamics??processes intimately linked to DRG1 function. This well-characterized background ensures reliable experimental outcomes and broad applicability.
DRG1 encodes a GTPase that occupies a pivotal node in translational control. It is activated downstream of mTORC1 in response to growth factors and amino acid availability, with AMPK providing regulatory input. DRG1 directly interacts with ZC3H15/DFRP1 and associates with ribosomal proteins and translation initiation factors to promote ribosome maturation. Additionally, it modulates stress granule assembly, bridging nutrient sensing and proteostasis. Genetic disruption of DRG1 consequently perturbs ribosome biogenesis, translational fidelity, and stress responsiveness.
In HEK293T cells, DRG1 knockout disrupts the highly active mTORC1-driven translational program. Defective ribosome assembly and altered polysome profiles are anticipated, alongside impaired stress granule dynamics following cellular stress. The polyclonal nature recapitulates the genetic heterogeneity seen in pathological contexts, offering a physiologically relevant platform to dissect DRG1??s role in proliferation and stress adaptation. This model thus advances the understanding of translation-related diseases and therapeutic interventions.
This knockout product enables a wide array of targeted investigations. Western blotting for DRG1, phosphorylated S6 kinase, and eIF4E confirms protein depletion and pathway activity. Polysome profiling and RNA-seq delineate perturbations in translation, while cell proliferation assays quantify growth defects. Stress granule imaging and mTOR pathway reporters elucidate dynamic stress responses. Such applications support cancer cell proliferation studies, drug target validation for translation-driven pathologies, and research into neurodegeneration and viral infection. For technical inquiries, contact Ascent Research.
